FLNA relative valueRV

FILANA THERAPEUTICS, INC.. How this company compares with the rest of its GICS sub-industry on the figures it reported in its last annual filing.

FLNA's return on equity of -122.3% ranks in the 43rd percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-07-31 and 2025-12-31.

As of . Source: SEC EDGAR XBRL company facts. Method and limitations.

Against 20 Biotechnology peers

10-K FY to 31 Dec 2025 in USD
MetricFLNAPeer medianPercentilen
Revenue FYn/a2.2M USDn/a13
Revenue YoYn/an/an/an/a
Gross marginn/an/an/an/a
Operating marginn/a-709.4%n/a10
Net marginn/a-510.8%n/a10
Return on equity-122.3%-106.1%43rd14
P / En/an/an/a1
1 yearn/an/an/an/a

Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal periods ending between 2025-07-31 and 2025-12-31. Prices as of 2026-09-21. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001437749-26-007962

Peer set, 20 companies

CRVO, GNTA, EDSA, CNTX, CELU, VERU, ATYR, KPTI, ALGS, KYNB, NXTC, MGX, ATNM, BCTX, BYSI, ANVS, MREO, SGMO, BRNS, QNCX

Left out: SEOVF (no annual filing), LITS (no annual filing), BETRF (period gap), CLCS (period gap), VICP (period gap).

What could not be compared

  • 69 The filer did not report this line in the filing used.
  • 26 The denominator is zero or negative, so the ratio has no meaning.
  • 20 The price series does not reach back to the start of this window.
  • 4 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
  • 3 This company's fiscal year ends more than 200 days from the subject's, so it is a different economic year.
  • 2 No annual filing (10-K, 20-F or 40-F) with fiscal-year figures.
  • 2 The newest price is more than 10 days old.
  • 1 This filer reports an ordinary share count and trades as a depositary receipt at a ratio Kresmion does not store, so price times shares would be wrong.
  • 1 No prior fiscal year in the same currency about twelve months earlier.

Free account

Open the relative value desk with a free account

An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, the filing behind every cell, and CSV. The table above stays free.

Create a free accountSign in

Cite this data

Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's GICS sub-industry. A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.

Upstream: SEC EDGAR XBRL company facts

Kresmion, "FLNA relative value, Kresmion", data as of 2026-03-12, https://kresmion.com/tools/relative-value/FLNA. Upstream data: SEC EDGAR XBRL company facts.